ARK持倉追蹤12.29 | 持續加倉阿裏和醫療股
以下數據爲Cathie Wood個人/所在機構的過往操作，其交易背後之投資邏輯並不明確，不代表投資建議，跟蹤操作注意風險。
【12.29持倉變化小結】
①連續三個交易日加倉任天堂，並從8月建倉以來一直持續加倉。任天堂10月美國售出73.5萬臺Switch按年升136%。
②連續三個交易日加倉騰訊控股，本月以來一直加倉。投行指出，反壟斷並非是政策“黑天鵝”，未來的方向有助於理順商業關係以及競爭關係，推動強監管金融領域補齊監管盲區。
③接連兩個交易日加倉阿裏巴巴，阿裏巴巴港股28日早間公告，增加公司股份回購計劃總額，由60億美元增加至100億美元。
④超過6個交易日持續賣出盈透證券，盈透證券2020年第三季度業績收益不及預期。
⑤昨日ARCT股票腰斬，（ARCT是Cathie Wood個人/所在機構所ARKG所持有的權重股票之一）拖累ARKG。ARKG ETF大跌7%，創多日以來最大單日跌幅。Cathie Wood昨日大部分操作基於ARKG ETF，大量買入醫療股票。
【ARK系列ETF介紹】
①ARKK：以顛覆性創新產業爲主要投資標的
ARKK專門投資革命性創新的公司，在5個美股ETF中，ARKK投資的公司類型最多元化，包括基因科技、全自動化、物聯網及金融科技相關的公司，可以說是其餘4個ETF的合體。
②ARKQ：以自動科技自動機器人技術爲主要投資標的
ARKQ投資的公司專注於機器人自動化相關的公司，當中投資自動駕駛的公司佔比最多，其次爲自動化機器人、3D打印、儲能技術、太空探索等的相關公司。
③ARKF ：以金融科技創新爲主要投資標的
ARKF主力投資金融科技相關公司，其中包括交易平臺、區塊鏈、衆籌平臺等等相關公司。
④ ARKW：以"下一代網絡"爲主要投資標的
ARKW專門投資"下一代網絡"的公司，當中佔比最多的公司爲雲計算、其次爲網絡安全、電子商務、大數據、人工智能等相關公司。
⑤ ARKG：以生物基因科技創新爲主要投資標的
ARKG這隻ETF主要專注於基因革命領域，包括基因編輯技術CRISPR、基因診斷治療、靶向治療、生物信息。
【Usmart目前支持部分ETF進行10倍槓桿日內交易，港股交易ETF無需繳納印花稅，對於日內短線交易而言，可降低交易成本】
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
